Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Drugs Today (Barc). 2011 Sep;47(9):647-51. doi: 10.1358/dot.2011.47.9.1688573.

Azilsartan medoxomil for the treatment of hypertension.

Author information

  • 1Thomson Reuters, Barcelona, Spain. scientific.prousjournals@thomsonreuters.com


The use of angiotensin receptor blockers (ARBs) represents a favorable approach for the control of blood pressure in patients with hypertension. Azilsartan medoxomil, a prodrug that undergoes rapid hydrolysis to its active moiety azilsartan, is an angiotensin AT(1) receptor antagonist with promising antihypertensive activity and a good safety profile. The agent has been evaluated as monotherapy and in combination with amlodipine or chlorthalidone in phase III trials in patients with essential hypertension. In 2011, azilsartan medoxomil was approved in the U.S. for the treatment of hypertension.

Copyright 2011 Prous Science, S.A.U. or its licensors. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Prous Science
    Loading ...
    Write to the Help Desk